Drug data last refreshed 16h ago · AI intelligence enriched 22h ago
PANDEL is a topical hydrocortisone probutate cream, a moderate-potency corticosteroid indicated for inflammatory skin conditions. It delivers localized anti-inflammatory benefits through dermal application without systemic absorption. The product targets patients with eczema, dermatitis, and other corticosteroid-responsive conditions.
Declining commercial footprint with minimal market presence signals limited team expansion and focus on retention or transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PANDEL presents limited career advancement opportunities given its LOE-approaching status and minimal job openings. Professionals joining this product should expect focus on market maintenance, generic transition management, and cost optimization rather than growth initiatives.
Worked on PANDEL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo